Standard Investments’s Revance Therapeutics, Inc. RVNC Stock Holding History

Standard Investments’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-47,846	Closed	-$992K	–	177
2015 Q1	$992K	Hold	47,846	–	–	0.06%	97
2014 Q4	$811K	Hold	47,846	–	–	0.04%	120
2014 Q3	$925K	Buy	47,846 +22,546	+89%	+$588K	0.05%	150
2014 Q2	$860K	Hold	25,300	–	–	0.05%	131
2014 Q1	$797K	Buy	+25,300	New	+$790K	0.07%	139

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

NHG

NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Standard Investments's RVNC Position: Q2 2015 in Review

Standard Investments sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2015, closing a stake of 47,846 shares — an estimated $992K sold.

Standard Investments first reported a position in RVNC in Q1 2014 and held it in 5 quarters. The position peaked at $992K in Q1 2015. 88 funds tracked by Wall St. Rank hold RVNC as of Q2 2015.

Standard Investments reported no remaining Revance Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
Standard Investments sold 47,846 Revance Therapeutics, Inc. shares in Q2 2015, an estimated $992K.
Standard Investments first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 5 quarters.
Standard Investments's Revance Therapeutics, Inc. position peaked at $992K in Q1 2015.
88 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2015.

Based on Standard Investments's 13F filing for Q2 2015, filed 14 Aug 2015.